newsfilter
← Latest News
GlobeNewswire·

GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression

Primary endpoint met in Phase 2 part of clinical trial for GH001 in TRD 7 of 8 patients (87.5%) were in remission (MADRS ≤10) at day 7 after dosing (p<0.0001) Secondary endpoints met Mean change from baseline in MADRS at day 7 after dosing wa